keyword
MENU ▼
Read by QxMD icon Read
search

RA treatment

keyword
https://www.readbyqxmd.com/read/29150737/risk-of-active-tuberculosis-in-patients-with-inflammatory-arthritis-receiving-tnf-inhibitors-a-look-beyond-the-baseline-tuberculosis-screening-protocol
#1
Alina Soare, Ana Maria Gheorghiu, Victoria Aramă, Dragoș Bumbăcea, Rucsandra Dobrotă, Raida Oneaţă, Simona Pintilie, Mihaela Milicescu, Ioan Ancuţa, Andrei Martin, Mariana Sasu, Claudia Ciofu, Liviu Macovei, Victor Stoica, Mihai Bojincă, Carina Mihai
Tuberculosis (TB) is a major concern in patients receiving TNF inhibitors (TNFi). This study aimed to assess the incidence of active TB and the efficacy of TB prevention measures used over the years, and to determine risk factors for developing TB, in a single-centre cohort of patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) receiving TNFi. Data of all patients in whom treatment with TNFi was initiated in our rheumatology clinic until December 1st 2014 have been retrospectively analysed...
November 17, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/29150565/the-role-of-macrophages-in-the-response-to-tnf-inhibition-in-experimental-arthritis
#2
Qi-Quan Huang, Robert Birkett, Renee Doyle, Bo Shi, Elyssa L Roberts, Qinwen Mao, Richard M Pope
The reduction of synovial tissue macrophages is a reliable biomarker for clinical improvement in patients with rheumatoid arthritis (RA), and macrophages are reduced in synovial tissue shortly after initiation of TNF inhibitors. The mechanism for this initial response is unclear. These studies were performed to identify the mechanisms responsible for the initial reduction of macrophages following TNF inhibition, positing that efflux to draining lymph nodes was involved. RA synovial tissue and synovial fluid macrophages expressed CCR7, which was increased in control macrophages following incubation with TNF-α...
November 17, 2017: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/29149929/gastrointestinal-and-hepatic-disease-in-rheumatoid-arthritis
#3
REVIEW
Ethan Craig, Laura C Cappelli
Gastrointestinal (GI) manifestations of rheumatoid arthritis (RA) are rare, but can be impactful for patients. Some GI processes are directly related to RA, whereas others may be sequelae of treatment or caused by concomitant autoimmune diseases. This article discusses the role of the GI tract in RA pathogenesis; the presentation, epidemiology, and diagnosis of RA-related GI manifestations; concomitant GI autoimmune diseases that may affect those with RA; and GI side effects of RA treatment. The importance of appropriately considering conditions unrelated to RA in the differential diagnosis when evaluating new GI symptoms in patients with RA is noted...
February 2018: Rheumatic Diseases Clinics of North America
https://www.readbyqxmd.com/read/29149783/hematological-improvement-of-patients-with-active-rheumatoid-arthritis-by-%C3%AE-d-mannuronic-acid-m2000-as-a-novel-nsaid-with-immunosuppressive-property
#4
Hossein Ahmadi, Ahmad Reza Jamshidi, Mahdi Mahmoudi, Farhad Gharibdoost, Mahdi Vojdanian, Mohammad Javad Fattahi, Noushin Rastkari, Zahra Aghazadeh, Abbas Mirshafiey
The aim of this study was to investigate the effect of β-D-mannuronic acid (M2000) on hematological parameters in patients with active rheumatoid arthritis. This study was conducted on 25 patients with active rheumatoid arthritis (RA) (identifier: IRCT2014011213739N2). M2000 was administered orally for anemic and non-anemic RA patients at a dose of 500 mg twice daily for 12 weeks. The patients were permitted to continue the conventional treatments excluding NSAIDs. Blood samples were collected at baseline, 4 and 12 weeks after drug administration and were tested for hematological parameters...
October 2017: Iranian Journal of Allergy, Asthma, and Immunology
https://www.readbyqxmd.com/read/29149648/dried-plum-alleviates-symptoms-of-inflammatory-arthritis-in-tnf-transgenic-mice
#5
Faryal Mirza, Joseph Lorenzo, Hicham Drissi, Francis Y Lee, Do Y Soung
Dried plum (DP), a rich source of polyphenols has been shown to have bone-preserving properties in both animal models of osteoporosis and postmenopausal women. We evaluated if DP alleviated the destruction of joints in transgenic mice (TG) that overexpress human tumor necrosis factor (TNF), a genetic model of rheumatoid arthritis (RA). A four-week treatment of 20% DP diet in TG slowed the onset of arthritis and reduced bone erosions in the joints compared to TG on a regular diet. This was associated with fewer tartrate-resistant acid phosphatase (TRAP) positive cells, suggesting decreased osteoclastogenesis...
October 16, 2017: Journal of Nutritional Biochemistry
https://www.readbyqxmd.com/read/29149289/rheumatoid-arthritis-patients-treated-in-trial-and-real-world-settings-comparison-of-randomized-trials-with-registries
#6
Gablu Kilcher, Noemi Hummel, Eva M Didden, Matthias Egger, Stephan Reichenbach
Objective: To investigate whether patients with RA enrolled in randomized controlled trials (RCTs) and observational studies may differ in terms of characteristics that could modify treatment effects, leading to an efficacy-effectiveness gap. Methods: We conducted systematic literature reviews to identify RCTs and observational studies with RA, treated with rituximab, tocilizumab or etanercept. We extracted baseline characteristics and compared the data of RCTs and observational studies using fixed-effects meta-analyses for the RCTs and random-effects meta-analyses for the observational studies...
November 14, 2017: Rheumatology
https://www.readbyqxmd.com/read/29148420/the-expression-of-mrna-for-peptidylarginine-deiminase-type-2-and-type-4-in-bone-marrow-cd34-cells-in-rheumatoid-arthritis
#7
Tatsuo Nagai, Yu Matsueda, Tetsuya Tomita, Hideki Yoshikawa, Shunsei Hirohata
OBJECTIVES: Antibodies directed to citrullinated proteins are highly specific for rheumatoid arthritis (RA). Citrullination is catalyzed by peptidylarginine deiminase (PAD) enzymes. The current study examined the mRNA expression of PADI2 and PADI4 in bone marrow (BM) CD34+ cells from RA patients. METHODS: CD34+ cells were purified from BM samples obtained from 48 RA patients and from 30 osteoarthritis (OA) patients during joint operations via aspiration from the iliac crest...
November 14, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29148406/high-3-year-golimumab-survival-in-patients-with-rheumatoid-arthritis-ankylosing-spondylitis-and-psoriatic-arthritis-real-world-data-from-328-patients
#8
Konstantinos Thomas, Irini Flouri, Argiro Repa, Kalliopi Fragiadaki, Petros P Sfikakis, Christos Koutsianas, Evripidis Kaltsonoudis, Paraskevi V Voulgari, Alexandros A Drosos, Evangelia Petrikkou, Prodromos Sidiropoulos, Dimitrios Vassilopoulos
OBJECTIVES: Our primary objective was to study the long-term survival on drug (SOD) of patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) treated with golimumab (GLM) in real life settings. METHODS: This was a retrospective, observational study of all patients treated with GLM in 4 Academic Centres in Greece during a 4-year period (09/2010-06/2014). SOD was analysed using Kaplan-Meier survival analysis, while Cox regression analysis estimating hazard ratios (HRs) for different baseline variables associated with drug discontinuation was performed for each disease...
November 9, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29148403/treatment-patterns-in-rheumatoid-arthritis-after-discontinuation-of-methotrexate-data-from-the-ontario-best-practices-research-initiative-obri
#9
Janet E Pope, Emmanouil Rampakakis, Mohammad Movahedi, Angela Cesta, Xiuying Li, Sandra Couto, John S Sampalis, Claire Bombardier
OBJECTIVES: In active rheumatoid arthritis (RA) patients with inadequate response to methotrexate (MTX), guidelines support adding or switching to another conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) and/or a biologic DMARD (bDMARD). The purpose of this analysis was to describe treatment practices in routine care and to evaluate determinants of regimen selection after MTX discontinuation. METHODS: Biologic-naïve patients in the Ontario Best Practice Research Initiatives registry discontinuing MTX due to primary/secondary failure, adverse events, or patient/physician decision were included...
October 23, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29147614/exploiting-a-new-strategy-to-induce-immunogenic-cell-death-to-improve-dendritic-cell-based-vaccines-for-lymphoma-immunotherapy
#10
B Montico, C Lapenta, M Ravo, D Martorelli, E Muraro, B Zeng, E Comaro, M Spada, S Donati, S M Santini, R Tarallo, G Giurato, F Rizzo, A Weisz, F Belardelli, R Dolcetti, J Dal Col
Although promising, the clinical benefit provided by dendritic cell (DC)-based vaccines is still limited and the choice of the optimal antigen formulation is still an unresolved issue. We have developed a new DC-based vaccination protocol for aggressive and/or refractory lymphomas which combines the unique features of interferon-conditioned DC (IFN-DC) with highly immunogenic tumor cell lysates (TCL) obtained from lymphoma cells undergoing immunogenic cell death. We show that treatment of mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) cell lines with 9-cis-retinoic acid and IFNα (RA/IFNα) induces early membrane exposure of Calreticulin, HSP70 and 90 together with CD47 down-regulation and enhanced HMGB1 secretion...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/29146743/testing-treat-to-target-outcomes-with-initial-methotrexate-monotherapy-compared-with-initial-tumour-necrosis-factor-inhibitor-adalimumab-plus-methotrexate-in-early-rheumatoid-arthritis
#11
Arthur Kavanaugh, Ronald van Vollenhoven, Roy M Fleischmann, Paul Emery, Iain Sainsbury, Stefan Florentinus, Su Chen, Benoît Guérette, Hartmut Kupper, Josef S Smolen
OBJECTIVES: To compare responses in patients with early rheumatoid arthritis (RA) initially treated with the tumour necrosis factor inhibitor (TNFi) adalimumab+methotrexate (MTX) versus MTX monotherapy who may have continued receiving MTX or switched to adalimumab rescue therapy after inadequate response to MTX. METHODS: OPTIMA enrolled MTX-naive patients with active RA for <1 year. This post hoc analysis determined the proportion of patients, stratified by initial treatment, who achieved28-joint modified Disease Activity Score based on C reactive protein <3...
November 16, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29146547/a-gene-module-associated-with-dysregulated-tcr-signaling-pathways-in-cd4-t-cell-subsets-in-rheumatoid-arthritis
#12
Shuji Sumitomo, Yasuo Nagafuchi, Yumi Tsuchida, Haruka Tsuchiya, Mineto Ota, Kazuyoshi Ishigaki, Shinichiro Nakachi, Rika Kato, Keiichi Sakurai, Norio Hanata, Shoko Tateishi, Hiroko Kanda, Akari Suzuki, Yuta Kochi, Keishi Fujio, Kazuhiko Yamamoto
We analyzed the transcriptome of detailed CD4(+) T cell subsets including them after abatacept treatment, and examined the difference among CD4(+) T cell subsets and identified gene sets that are closely associated disease activity and abatacept treatment. Seven CD4(+) T cell subsets (naive, Th1, Th17, Th1/17, nonTh1/17, Tfh and Treg) were sorted from PBMCs taken from 10 RA patients and 10 healthy controls, and three RA patients donated samples before and 6 months after abatacept treatment. Paired-end RNA sequencing was performed using HiSeq 2500...
November 13, 2017: Journal of Autoimmunity
https://www.readbyqxmd.com/read/29146040/-effectiveness-therapeutic-maintenance-and-reasons-for-stopping-tocilizumab-tcz-a-retrospective-and-monocentric-study-in-88%C3%A2-patients-followed-for-rheumatoid-arthritis-ra-at-the-reims-university-hospital
#13
Clément Chopin, Loïc Pauvelle, Sarah Jaulerry, Pascal Brochot, Jean-Paul Eschard, Jean-Hugues Salmon
OBJECTIVE: Study the therapeutic maintenance, efficacy and reasons for tocilizumab stop in daily practice. PATIENTS AND METHODS: A monocentric, retrospective study of patients treated for rheumatoid arthritis who received at least one TCZ infusion between January 2009 and December 2015. Therapeutic maintenance was evaluated using the Kaplan-Meier method. The efficacy of TCZ was measured by DAS28 and the EULAR response. Reasons for stopping and new treatment lines were also collected...
October 18, 2017: Thérapie
https://www.readbyqxmd.com/read/29145862/l161982-alleviates-collagen-induced-arthritis-in-mice-by-increasing-treg-cells-and-down-regulating-interleukin-17-and-monocyte-chemoattractant-protein-1-levels
#14
Liang Chen, Xianglei Wu, Jun Zhong, Dongqing Li
BACKGROUND: To investigate the effects and potential mechanism of L161982 (a kind of EP4 antagonist) on the collagen-induced arthritis (CIA) mice model. METHODS: The CIA mice model were first established by immunizing with Chicken Type II Collagen on DBA/1 mice. The CIA groups were administered once a day for 2 weeks with either 5 mg/kg L161982 by intraperitoneal injections (IP), 200 U celecoxib by intragastrical injections, or 100 μl PBS (IP). At the end of the study, total arthritis score and histopathologic examination were assessed to determine CIA severity...
November 16, 2017: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/29145756/micronutrients-and-natural-compounds-status-and-their-effects-on-wound-healing-in-the-diabetic-foot-ulcer
#15
Kanokwan Kulprachakarn, Sakaewan Ounjaijean, Jukkrit Wungrath, Raj Mani, Kittipan Rerkasem
The diabetic foot ulcer (DFU) is an invariably common complication of diabetes mellitus, it is also a significant cause of amputation as well as extended hospitalization. As most patients with DFU suffer from malnutrition, which has been related to improper metabolic micronutrients status, alterations can affect impaired wound healing process. Micronutrients and herbal remedies applications present a wide range of health advantages to patients with DFU. The purpose of this review is to provide current evidence on the potential effect of dietary supplementations such as vitamins A, C, D, E, magnesium, zinc, copper, iron, boron, and such naturally occurring compounds as Aloe vera, Naringin, and Radix Astragali (RA) and Radix Rehmanniae (RR) in the administration of lower extremity wounds, especially in DFU, and to present some insights for applications in the treatment of DFU patients in the future...
November 1, 2017: International Journal of Lower Extremity Wounds
https://www.readbyqxmd.com/read/29145473/suppression-and-resolution-of-autoimmune-arthritis-by-rhesus-%C3%AE-defensin-1-an-immunomodulatory-macrocyclic-peptide
#16
Justin B Schaal, Dat Q Tran, Akshay Subramanian, Reshma Patel, Teresina Laragione, Kevin D Roberts, Katie Trinh, Prasad Tongaonkar, Patti A Tran, Dmitriy Minond, Gregg B Fields, Paul Beringer, André J Ouellette, Percio S Gulko, Michael E Selsted
θ-defensins constitute a family of macrocyclic peptides expressed exclusively in Old World monkeys. The peptides are pleiotropic effectors of innate immunity, possessing broad spectrum antimicrobial activities and immunoregulatory properties. Here we report that rhesus θ-defensin 1 (RTD-1) is highly effective in arresting and reversing joint disease in a rodent model of rheumatoid arthritis (RA). Parenteral RTD-1 treatment of DA/OlaHsd rats with established pristane-induced arthritis (PIA) rapidly suppressed joint disease progression, restored limb mobility, and preserved normal joint architecture...
2017: PloS One
https://www.readbyqxmd.com/read/29143933/long-term-effectiveness-of-tocilizumab-in-patients-with-rheumatoid-arthritis-stratified-by-number-of-previous-treatment-failures-with-biologic-agents-results-from-the-german-rabbit-cohort
#17
Lisa Baganz, Adrian Richter, Jörn Kekow, Arnold Bussmann, Andreas Krause, Carsten Stille, Joachim Listing, Angela Zink, Anja Strangfeld
In Germany, Tocilizumab (TCZ) is used for the treatment of rheumatoid arthritis both in biologic-naïve patients and those with previous failures of biologic disease-modifying antirheumatic drugs (bDMARDs). The long-term effectiveness and retention rates of TCZ in patients with different numbers of prior bDMARD failures has rarely been investigated. We included 885 RA patients in the analyses, enrolled with the start of TCZ between 2009 and 2015 in the German biologics register RABBIT. Patients were stratified according to prior bDMARD failures: no prior bDMARD or 1, 2 or ≥ 3 bDMARD failures...
November 16, 2017: Rheumatology International
https://www.readbyqxmd.com/read/29142041/occurrence-of-serious-infection-in-patients-with-rheumatoid-arthritis-treated-with-biologics-and-denosumab-observed-in-a-clinical-setting
#18
Arthur N Lau, Matthew Wong-Pack, Rod Rodjanapiches, George Ioannidis, Sally Wade, Leslie Spangler, Akhila Balasubramanian, Nicola Pannacciulli, Celia J F Lin, Patrick Roy-Gayos, William G Bensen, Robert Bensen, Jonathan D Adachi
OBJECTIVE: Previous studies combining biologic disease-modifying antirheumatic drugs (bDMARD) to treat rheumatoid arthritis (RA) have shown an increased risk of infection. However, the risk of infection with concurrent use of denosumab, a biologic agent for the treatment of osteoporosis, and a bDMARD remains unclear. Here, we evaluated the incidence of serious and opportunistic infections in patients treated concurrently with denosumab and a bDMARD and patients treated with a bDMARD alone...
November 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/29142036/effect-of-glucocorticoids-on-the-clinical-and-radiographic-efficacy-of-tofacitinib-in-patients-with-rheumatoid-arthritis-a-posthoc-analysis-of-data-from-6-phase-iii-studies
#19
Christina Charles-Schoeman, Désirée van der Heijde, Gerd R Burmester, Peter Nash, Cristiano A F Zerbini, Carol A Connell, Haiyun Fan, Kenneth Kwok, Eustratios Bananis, Roy Fleischmann
OBJECTIVE: Tofacitinib has been investigated for the treatment of rheumatoid arthritis (RA) in phase III studies in which concomitant glucocorticoids (GC) were allowed. We analyzed the effect of GC use on efficacy outcomes in patients with RA receiving tofacitinib and/or methotrexate (MTX) or conventional synthetic disease-modifying antirheumatic drugs (csDMARD) in these studies. METHODS: Our posthoc analysis included data from 6 phase III studies (NCT01039688; NCT00814307; NCT00847613; NCT00853385; NCT00856544; NCT00960440)...
November 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/29142030/plasma-microrna-profiles-in-patients-with-early-rheumatoid-arthritis-responding-to-adalimumab-plus-methotrexate-vs-methotrexate-alone-a-placebo-controlled-clinical-trial
#20
Jacob Sode, Sophine B Krintel, Anting Liu Carlsen, Merete L Hetland, Julia S Johansen, Kim Hørslev-Petersen, Kristian Stengaard-Pedersen, Torkell Ellingsen, Mark Burton, Peter Junker, Mikkel Østergaard, Niels H H Heegaard
OBJECTIVE: The aim was to identify plasma (i.e., cell-free) microRNA (miRNA) predicting antitumor necrosis and/or methotrexate (MTX) treatment response in patients enrolled in an investigator-initiated, prospective, double-blinded, placebo-controlled trial (The OPERA study, NCT00660647). METHODS: We included 180 disease-modifying antirheumatic drug-naive patients with early rheumatoid arthritis (RA) randomized to adalimumab (ADA; n = 89) or placebo (n = 91) in combination with MTX...
November 15, 2017: Journal of Rheumatology
keyword
keyword
91514
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"